News

News Subscription

Dec 23. 2024 / Ad hoc announcement
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
Read more
Download
Dec 16. 2024 / Ad hoc announcement
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Read more
Download
Oct 10. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year
Read more
Download
Sep 24. 2024
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
Read more
Download
Sep 19. 2024 / Ad hoc announcement
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
Read more
Download
Sep 06. 2024 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
Read more
Download
Aug 27. 2024 / Ad hoc announcement
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
Read more
Download
Aug 21. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Aug 13. 2024 / Ad hoc announcement
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
Read more
Download
Jun 20. 2024
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Read more
Download